 |
While workshops to solicit stakeholder feedback for the Food and Drug Omnibus Reform Act (“FDORA”) diversity plan mandate are still pending—and while waivers may be available for certain cases—clinical trial sponsors should prepare for the possibility of diversity plan recommendations becoming diversity plan requirements. As such, many sponsors are wondering how to recruit, engage and retain hard-to-find patients. In this playbook, we explore trends and how sponsors can adapt their protocols to be more inclusive of more people:
|
